Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.83 |
| ▸ | ILK | Q13418 | 4/20 | 0.83 |
| ▸ | GAK | O14976 | 3/20 | 0.83 |
| ▸ | PLK4 | O00444 | 1/20 | 0.83 |
| ▸ | CIT | O14578 | 1/20 | 0.83 |
| ▸ | AURKA | O14965 | 1/20 | 0.83 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.83 |
| ▸ | BUB1 | O43683 | 1/20 | 0.83 |
| ▸ | KDM1A | O60341 | 1/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.83 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.83 |
| ▸ | STK17B | O94768 | 1/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL465281 | 0.99 | EGFR (0.83) | EGFRERBB2ILKGAKPLK4 | |
| SCHEMBL1286655 | 0.94 | EGFR (0.74) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL28576829 | 0.92 | EGFR (0.98) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL3667407 | 0.91 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL8413 | 0.91 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL29351329 | 0.91 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL30362833 | 0.91 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL16767632 | 0.90 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL417841 | 0.90 | EGFR (0.98) | EGFRERBB2ILKGAKPLK4 | |
| Erlotinib SCHEMBL21176918 | 0.90 | EGFR (1.00) | EGFRERBB2ILKGAKPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402557-B2 | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor | MILLER PENELOPE ELIZABETH | 2008-07-22 | — | — | US | claimed |
| WO-2011068404-A3 | ADMINISTRATION OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2- METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE SALT BY INHALATION | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011068403-A3 | NOVEL N-{3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMJNE SALTS | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011068404-A2 | ADMINISTRATION OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2- METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE SALT BY INHALATION | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068404-A2 | ADMINISTRATION OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2- METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE SALT BY INHALATION | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068403-A2 | NOVEL N-{3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMJNE SALTS | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068403-A2 | NOVEL N-{3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMJNE SALTS | ULTIMORPHIX TECHNOLOGIES B.V. (NL) | 2011-06-09 | — | — | WO | disclosed |